National Institute of Allergy and Infectious Diseases (NIAID)
This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (SGB or Sham) administered to adults with Long COVID (Figure 1) followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 at Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. Follow-up visits at weeks 12 and 26 allow for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures.
This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (Stellate Ganglion Block (SGB) or Sham) administered to adults with Long COVID followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure te…
Inclusion Criteria: 1. Aged 18 to 65 years, inclusive, at the time of consent. 2. History of SARS-CoV-2 infection\*a-d 1. Shown by (1) a positive nucleic acid amplification test (NAAT) or antigen test,\*b OR (2) meeting clinical criteria AND an epidemiologic link to a confirmed case.\*c,d 2. See Section 8.1, Visit 00A, for a list of acceptable documentation required to confirm past SARS CoV-2 infections. 3. Clinical criteria is defined as either (1) acute onset of fever AND cough (influenza like illness); OR (2) acute altered/loss of taste or smell + one additional symptom including…
Bupivacaine hydrochloride injection (without epinephrine) is a long-acting amide-type local anesthetic commonly used for the production of local or regional anesthesia and analgesia in a variety of clinical settings, including surgical, obstetrical, and diagnostic procedures. It is typically administered via local infiltration, peripheral nerve block, or epidural or spinal routes in sterile isotonic solution formulations.
Lidocaine is a local anesthetic of the amide group. Intradermal lidocaine hydrochloride injection is a local anesthetic administered into the superficial layers of the skin. It is commonly used prior to minor procedures including the formation of an intradermal skin wheal. When administered intradermally, lidocaine hydrochloride produces localized numbness without affecting consciousness.